Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7420059 | 1.00 | NPSR1 (0.50) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 | |
| SCHEMBL374351 | 0.97 | NPSR1 (0.52) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 | |
| SCHEMBL990527 | 0.92 | — | — | |
| SCHEMBL390361 | 0.87 | — | — | |
| SCHEMBL34476145 | 0.79 | NPSR1 (0.37) | NPSR1CYP4F2CYP4A11KDM4ELMNA | |
| SCHEMBL2077252 | 0.79 | NPSR1 (0.37) | NPSR1CYP4F2CYP4A11CYP3A4KMT2A | |
| SCHEMBL20740435 | 0.78 | NPSR1 (0.48) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 | |
| SCHEMBL1604408 | 0.78 | NPSR1 (0.48) | NPSR1MAPTCYP4F2CYP4A11CYP3A4 | |
| Hydrochloric Acid SCHEMBL2077250 | 0.78 | NPSR1 (0.36) | NPSR1CYP4F2CYP4A11KMT2AKDM4E | |
| SCHEMBL15821205 | 0.77 | CYP2C19 (0.35) | NPSR1KDM4EALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-3184512-B1 | ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE | MASSACHUSETTS GEN HOSPITAL (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3184512-B1 | ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE | MASSACHUSETTS GEN HOSPITAL (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3107916-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-03-20 | — | — | EP | disclosed |
| EP-3107916-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-03-20 | — | — | EP | disclosed |
| CN-105793266-B | Spiro-oxazolones | 豪夫迈·罗氏有限公司 | 2019-02-12 | — | — | CN | disclosed |
| US-10154991-B2 | Anesthetic compounds and related methods of use | ANNOVATION BIOPHARMA, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| CN-109020936-A | A kind of preparation method of Spiromesifen and its intermediate | 山东康乔生物科技有限公司 | 2018-12-18 | — | — | CN | disclosed |
| US-20180098968-A1 | ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| WO-2008002886-A2 | PHOSPHONIUM SALTS FOR POLYMER COMPOSITES AND THEIR PREPARATION | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-01-03 | — | — | WO | disclosed |
| EP-1869099-A2 | POLYARYLATE COMPOSITIONS AND ARTICLES THEREFROM | General Electric Company (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007084664-A2 | FLAME RETARDANT RESIN COMPOSITION | GENERAL ELECTRIC COMPANY (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2006107940-A2 | POLYARYLATE COMPOSITIONS AND ARTICLES THEREFROM | GENERAL ELECTRIC COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
| US-6444616-B1 | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-03 | — | — | US | disclosed |
| US-6130225-A | Substituted p-trifluoromethylphenyluracils | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | disclosed |
| EP-0923562-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AG (DE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998006706-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |
| US-4785132-A | CATALYTIC HYDROGENATION OF HYDROXYBENZOIC ACIDS | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1988-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | AVPR1A, AVPR1B, AVPR2 | NPSR1 16/4885MAPT 1576/4885CYP4F2 1456/4885 |
| US-11718602-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | NPSR1 2660/4885MAPT 2974/4885CYP4F2 4314/4885 |
| US-10154991-B2 | Anesthetic compounds and related methods of use | OPRM1, OPRK1, OPRL1 | NPSR1 365/4885MAPT 1920/4885CYP4F2 75/4885 |
| US-20180098968-A1 | ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE | OPRM1, OPRK1, OPRL1 | NPSR1 365/4885MAPT 1920/4885CYP4F2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.